Table 1. Differentially expressed genes (DEGs) and related KEGG Pathways.
| DEGs associated with immunity and signal transduction pathways (at 12h post saline/LPS treatment) | ||||
|---|---|---|---|---|
| No. of DEGs | Upregulated genes | Downregulated genes | Pathway | P-value |
| 10 | PIK3CA, LOC107056430, LCP2, MAPK9, PIK3CG | LOC107050724, LOC107056737, TAGLN, LOC107057160, LOC101750560 | Fc epsilon RI signaling pathway (ko04664) | 0.003053823 |
| 12 | PIK3CA, IL15, CCLI10, MAPK9, RPS6KA5, PIK3CG | RLTPR, CNN1, LOC107057160, LOC101750560, LOC107050645, TAGLN, | TNF signaling pathway (ko04668) | 0.00772329 |
| 15 | PIK3CA, LOC107056430, CCLI10, CCR2, DOCK10, DOCK2, PIK3CG, CXCL14, CXCL12 | LOC107050724, SASH3, PYGO2, LOC101750560, PDLIM7, TAGLN | Chemokine signaling pathway (ko04062) | 0.008371477 |
| 24 | NID1, F13A1, PIK3CA, MMP2, FGL1, CXCL12, LOC107056639, ITGAV, SPECC1L, CDH5, PIK3CG | TESPA1, ACTN4, TAGLN, MYL9, PDLIM7, LOC107057430, LOC107050460, LOC107050724, LOC101750377, LOC101747592, LOC107056858, LOC107050373, LOC107051991 | Leukocyte transendothelial migration (ko04670) | 0.00961218 |
| 9 | PIK3CA, LOC107056430, PAK3, MAPK9, PIK3CG | SASH3, PYGO2, LOC107057160, LOC101750560 | ErbB signaling pathway (ko04012) | 0.02833687 |
| 10 | PIK3CA, LOC107056737, DOCK10, PIK3CG | LOC107050724, SASH3, CFL2, LOC101750560, TAGLN, DOCK2 | Fc gamma R-mediated phagocytosis (ko04666) | 0.03687679 |
| 9 | BPI, TLR2A, PIK3CA, CD28, CCLI10, MAPK9, PIK3CG, LOC107057160 | LOC107057160, LOC101750560 | Toll-like receptor signaling pathway (ko04620) | 0.05084102 |
| 18 | IL1R2, LOC107056430, PDGFRA, FGF7, MAPK9, TGFBR1, RPS6KA5 | HSPB1, SASH3, CNN1, JUN-D, LOC107057160, LOC101750560, RPS6KA3, CDC25B, LOC107051014, TAGLN, FLNA |
MAPK signaling pathway (ko04010) |
0.06491393 |
| DEGs associated with cancer pathways (at 12h post saline/LPS treatment) | ||||
|---|---|---|---|---|
| 26 | PIK3CA, DICER1, MMP2, FGL1, FGF7, GOLIM4, LOC107056430, PDGFRA, ZEB2, HNRPK, RPS6KA5, PIK3CG, LOC107056494 | LOC107057430, LOC107050460, LOC101750377, SASH3, E2F1, LOC107056068, PYGO2, TPM1, LOC101747592, LOC107050373, TESPA1, RASSF1, CDC25B | MicroRNAs in cancer (ko05206) | 0.00172622 |
| 8 | LOC107056430, FGF7, RPS6KA5, LOC107055989, MMP2, LOC107056858 | E2F1, RASSF1 | Bladder cancer (ko05219) | 0.008974338 |
| 30 | PIK3CA, MMP2, FGL1, LOC107056430, FGF7, LOC107055989, FAM46C, LOC107056858, NID1, TLR2A, F13A1, PIK3CG, NUDT16L1, DCN, ITPR2, LUM, LOC107056639, ITGAV | TESPA1, PDLIM7, FLNA, TAGLN, LOC107056482, LOC107057430, LOC107050460, LOC101750377, LOC101747592, LOC107050373, LOC101750560, LOC107050724 | Proteoglycans in cancer (ko05205) | 0.01710184 |
| 11 | PIK3CA, LOC107056430, FGF7, PIK3CG, PDGFRA, GSTA3 | E2F1, LOC101750560, CDK2, LOC107050491, LOC107056196 | Prostate cancer (ko05215) | 0.02190454 |
| 7 | PIK3CA, PIK3CG, TGFBR1, MAPK9, JAK1 | E2F1, LOC101750560 | Pancreatic cancer (ko05212) | 0.02477662 |
| 8 | PIK3CA, LOC107056430, PDGFRA, PIK3CG, LOC107056858, FGF7 | E2F1, LOC101750560 | Melanoma (ko05218) | 0.02656947 |
| 8 | PIK3CA, LOC107056430, PIK3CG, PDGFRA | PYGO2, E2F1, LOC101750560, CABP2 | Glioma (ko05214) | 0.03668416 |
| 8 | PIK3CA, LOC107056430, PIK3CG, TGFBR1 | SASH3, PYGO2, E2F1, LOC101750560 | Chronic myeloid leukemia (ko05220) | 0.03810799 |
| DEGs associated with metabolic pathways (at 12h post saline/LPS treatment) | ||||
|---|---|---|---|---|
| 14 | ATP5A1W, ATP12A | ATP5D, LOC107056507, SDHC, LOC107049545, NDUFA13, ATP5G2, NDUFA2, Dock11, LOC107049047, COX5A | Oxidative phosphorylation (ko00190) | 0.00017938 |
| 5 | ALDH1A3, IL4I1, | LOC107056850, MIF, LOC107049269 | Phenylalanine metabolism (ko00360) | 0.001328849 |
| 4 | ----------- | LSS, SC5D, LOC100857622, LOC107056717 | Steroid biosynthesis (ko00100) | 0.009269242 |
| 4 | ----------- | CHURC1, LOC107055323, FDPS, LOC107049309 | Terpenoid backbone biosynthesis (ko00900) | 0.01784414 |
| 4 | GSTA3, ALDH1A3 | LOC107050491, LOC107056196 | Drug metabolism - cytochrome P450 (ko00982) | 0.04348163 |
| DEGs associated with all significant pathways(at 36h post saline/LPS treatment) | ||||
|---|---|---|---|---|
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Graft-versus-host disease (ko05332) | 0.000271798 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Allograft rejection (ko05330) | 0.000503261 |
| 5 | LOC107049120, YF6, LOC768350, BG2 | THBS1 | Phagosome (ko04145) | 0.000544606 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Antigen processing and presentation (ko04612) | 0.000688693 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Primary immunodeficiency (ko05340) | 0.000730337 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Autoimmune thyroid disease (ko05320) | 0.001049398 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Natural killer cell mediated cytotoxicity (ko04650) | 0.00364005 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | T cell receptor signaling pathway (ko04660) | 0.00433848 |
| 4 | LOC107049120, YF6, LOC768350, BG2 | Endocytosis (ko04144) | 0.004680683 | |
| 3 | LOC107049120, YF6, LOC768350 |
----------- | Hematopoietic cell lineage (ko04640) | 0.007984066 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Herpes simplex infection (ko05168) | 0.008757677 |
| 4 | LOC107049120, YF6, LOC768350 | THBS1 | Cell adhesion molecules (ko04514) | 0.009543652 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Viral carcinogenesis (ko05203) | 0.01212585 |
| 3 | LOC107049120, YF6, LOC768350 | ----------- | Epstein-Barr virus infection (ko05169) | 0.01801051 |
| DEGs associated with all significant pathways (at 72h post saline/LPS treatment) | ||||
|---|---|---|---|---|
| 4 | ----------- | LOC769899, AVD, AVR2, LOC768350 | Graft-versus-host disease (ko05332) | 0.000462069 |
| 4 | ----------- | LOC769899, AVD, AVR2, LOC768350 | Allograft rejection (ko05330) | 0.001016396 |
| 6 | CTGF, CYR61 | LOC769899, AVD, AVR2, LOC768350 | Hematopoietic cell lineage (ko04640) | 0.001108016 |
| 4 | ----------- | LOC769899, AVD, AVR2, LOC768350 | Antigen processing and presentation (ko04612) | 0.001513009 |
| 4 | ----------- | LOC769899, AVD, AVR2, LOC768350 | Primary immunodeficiency (ko05340) | 0.001629486 |
| 4 | LOC100857334, LOC770025, LOC107049046, 107055485 | ----------- | Ribosome (ko03010) | 0.001710519 |
| 6 | ----------- | LOC769899, AVD, AVR2, LOC768350, LOC107055757, HNRPK | Viral carcinogenesis (ko05203) | 0.002413858 |
| 5 | FOS | LOC769899, AVD, AVR2, LOC768350 | T cell receptor signaling pathway (ko04660) | 0.002489395 |
| 4 | ----------- | LOC769899, AVD, AVR2, LOC768350 | Autoimmune thyroid disease (ko05320) | 0.002569968 |
| 7 | CTGF, CYR61, LOC100857858 | LOC769899, AVD, AVR2, LOC768350 | Phagosome (ko04145) | 0.003478134 |
| 4 | ----------- | LOC769899, AVD, AVR2, LOC768350 | Natural killer cell mediated cytotoxicity (ko04650) | 0.01183826 |
| 2 | ----------- | LOC107052718, LOC107052719 | Folate biosynthesis (ko00790) | 0.01851986 |
| 5 | CTGF, FOS, LOC107049866, LOC107049603, CYR61 | ----------- | Osteoclast differentiation (ko04380) | 0.03108378 |
| 6 | CTGF, CYR61 | LOC769899, AVD, AVR2, LOC768350 | Cell adhesion molecules (ko04514) | 0.03301481 |
| 2 | FOS, LOC769000 | ----------- | Colorectal cancer (ko05210) | 0.03620476 |
| 5 | LOC769000 | LOC769899, AVD, LOC768350, AVR2 | Endocytosis (ko04144) | 0.04666407 |